GC Green Cross, Additional Production of COVID-19 Plasma Therapy

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross announced on the 14th that it has completed the production of a batch for patient treatment purposes of the COVID-19 plasma therapy.

According to GC Green Cross, unlike the first batch produced for clinical trial purposes, this production batch is mainly intended for the treatment of COVID-19 patients in medical settings. The plasma used this time was 240ℓ, about four times more than the amount used in the first batch.

GC Green Cross received approval from the Ministry of Food and Drug Safety in August for the Phase 2 clinical trial plan of the plasma therapy 'GC5131' and is conducting trials at six hospitals. Depending on the clinical progress, if it is judged that the therapy can be used for patient treatment at hospitals, it can be used for patients who are in critical condition or have no alternative treatment options under the approval of the Ministry of Food and Drug Safety.

Meanwhile, due to the nature of the plasma therapy, production is limited to the amount of plasma secured from COVID-19 recovered patients. To secure plasma, GC Green Cross has expanded the blood collection institutions from the previous four medical institutions to 46 nationwide 'Blood Donation Houses' in cooperation with health authorities and the Red Cross.

Kim Jin, head of the medical department at GC Green Cross, said, "The plasma therapy is a treatment developed by the power of our people," and added, "We ask for active interest and participation so that the treatment to be used in medical settings can be developed quickly."

This content was produced with the assistance of AI translation services.